Actionable news
All posts from Actionable news
Actionable news in FGEN: FIBROGEN INC,

FibroGen (FGEN( and ​MyoKardia (MYOK) shares soar on positive news: Zynerba (ZYNE) and Gemphire (GEMP) plunge on poor data

Price and Volume Movers

FibroGen, Inc. (NASDAQ:FGEN) shares have soared after-hours, currently trading up 61% to $33.40. The company announced that top-line data from its Phase 2 trial of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF) met the primary efficacy endpoint of change of forced vital capacity percent predicted.

MyoKardia, Inc. (Nasdaq:MYOK) shares surged to close up 83% following positive top-line data from the first patient cohort of its Phase 2 PIONEER-HCM study of mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy (oHCM) patients. The first cohort met the primary as well as key secondary endpoints. It expects to initiate its next trial, EXPLORER-HCM, potentially a pivotal study, by the end of this year. The company also noted that data from its second, low-dose patient cohort in PIONEER-HCM has completed enrollment with top-line data due 1Q 2018.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) slumped to close down 56% to $6.67 following the release of top-line results from its Phase 2 STAR 1 trial evaluating ZYN002 in adult epilepsy patients with focal seizures. Both primary and secondary endpoints were not met with no statistically significant differences between ZYN002 and placebo.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) announced top-line data from its Phase 2b ROYAL-1 trial of oral gemcabene. The trial met its primary endpoint, however, its mean percent change in LDL cholesterol of -17.2% vs -5.5% for placebo was...